{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:09:11Z","timestamp":1791929351598,"version":"4.3.4"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Pathogenesis of lung injury in COVID-19 is not completely understood, leaving gaps in understanding how current treatments modulate the course of COVID-19. Neutrophil numbers and activation state in circulation have been found to correlate with COVID-19 severity, and neutrophil extracellular traps (NETs) have been found in the lung parenchyma of patients with acute respiratory distress syndrome (ARDS) in COVID-19. Targeting the pro-inflammatory functions of neutrophils may diminish lung injury in COVID-19 and ARDS. Neutrophils were isolated from peripheral blood of healthy donors, treated\n                    <jats:italic>ex vivo<\/jats:italic>\n                    with dexamethasone, tocilizumab and intravenous immunoglobulin (IVIG) and NET formation, oxidative burst, and phagocytosis were assessed. Plasma from critically ill COVID-19 patients before and after clinical treatment with IVIG and from healthy donors was assessed for neutrophil activation-related proteins. While dexamethasone and tocilizumab did not affect PMA- and nigericin-induced NET production\n                    <jats:italic>ex vivo<\/jats:italic>\n                    , IVIG induced a dose-dependent abrogation of NET production in both activation models. IVIG also reduced PMA-elicited reactive oxygen species production, but did not alter phagocytosis. COVID-19 patients were found to have elevated levels of cell-free DNA, neutrophil elastase and IL-8 as compared to healthy controls. Levels of both cell-free DNA and neutrophil elastase were lower 5 days after 4 days of daily treatment with IVIG. The lack of impact of dexamethasone or tocilizumab on these neutrophil functions suggests that these therapeutic agents may not act through suppression of neutrophil functions, indicating that the door might still be open for the addition of a neutrophil modulator to the COVID-19 therapeutic repertoire.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.993720","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T08:18:22Z","timestamp":1666253902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin"],"prefix":"10.3389","volume":"13","author":[{"given":"Jorge Adrian","family":"Masso-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarod","family":"Olay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Groysberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Geriak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Nizet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Crotty Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00471","article-title":"How neutrophils shape adaptive immune responses","volume":"6","author":"Leliefeld","year":"2015","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84538","article-title":"Neutrophil extracellular traps - the dark side of neutrophils","volume":"126","author":"Sorensen","year":"2016","journal-title":"J Clin Invest."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00678","article-title":"NETopathies? unraveling the dark side of old diseases through neutrophils","volume":"7","author":"Mitsios","year":"2017","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02171","article-title":"Update on neutrophil function in severe inflammation","volume":"9","author":"Mortaz","year":"2018","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.71","article-title":"The role of neutrophils and NETosis in autoimmune and renal diseases","volume":"12","author":"Gupta","year":"2016","journal-title":"Nat Rev Nephrology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040915","article-title":"Neutrophil extracellular traps (NETs) take the central stage in driving autoimmune responses","volume":"9","author":"Fousert","year":"2020","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab437","article-title":"Increased peripheral blood neutrophil activation phenotypes and neutrophil extracellular trap formation in critically ill coronavirus disease 2019 (COVID-19) patients: A case series and review of the literature","volume":"74","author":"Masso-Silva","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B9","article-title":"Acute respiratory distress syndrome: Diagnosis and management","volume":"101","author":"Saguil","year":"2020","journal-title":"Am Fam Physician"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864387","article-title":"Neutrophils in COVID-19: Not innocent bystanders","volume":"13","author":"McKenna","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.572009","article-title":"Targeting neutrophils to treat acute respiratory distress syndrome in coronavirus disease","volume":"11","author":"Chiang","year":"2020","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00113","article-title":"Neutrophil: A cell with many roles in inflammation or several cell types","volume":"9","author":"Rosales","year":"2018","journal-title":"Front Physiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00081","article-title":"Neutrophil extracellular traps and its implications in inflammation: an overview","volume":"8","author":"Delgado-Rizo","year":"2017","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060815-014442","article-title":"Reactive oxygen species and neutrophil function","volume":"85","author":"Winterbourn","year":"2016","journal-title":"Annu Rev Biochem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: Quintiles prize lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"Br J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(22)00018-8","article-title":"Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO clinical characterisation protocol UK: prospective, cohort study","volume":"4","author":"N\u00e4rhi","year":"2022","journal-title":"Lancet Digital Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.598308","article-title":"Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: A comprehensive review of available and emerging evidence at the peak of the pandemic","volume":"11","author":"Cavalli","year":"2020","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.2209","article-title":"Effectiveness of tocilizumab in patients hospitalized with COVID-19: A follow-up of the CORIMUNO-TOCI-1 randomized clinical trial","volume":"181","author":"Mariette","year":"2021","journal-title":"JAMA Internal Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e2","article-title":"COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence - 25 U.S. jurisdictions, April 4-December 25, 2021","volume":"71","author":"Johnson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.132","article-title":"Neutrophils in the pathogenesis and manifestations of SLE","volume":"7","author":"Kaplan","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93897","article-title":"Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target","volume":"2","author":"Knight","year":"2017","journal-title":"JCI Insight"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao3089","article-title":"Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis","volume":"10","author":"Maugeri","year":"2018","journal-title":"Sci Trans Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500059633","article-title":"IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients","volume":"38","author":"Shoenfeld","year":"2005","journal-title":"Autoimmunity"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000511376","article-title":"Use of intravenous immunoglobulin (Prevagen or octagam) for the treatment of COVID-19: Retrospective case series","volume":"99","author":"Herth","year":"2020","journal-title":"Respiration"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000280","article-title":"Intravenous immunoglobulin plus methylprednisolone mitigate respiratory morbidity in coronavirus disease 2019","volume":"2","author":"Sakoulas","year":"2020","journal-title":"Crit Care Explor"},{"key":"B28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12879-020-05507-4","article-title":"The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial","volume":"20","author":"Gharebaghi","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab098","article-title":"A phase II safety and efficacy study on prognosis of moderate pneumonia in coronavirus disease 2019 patients with regular intravenous immunoglobulin therapy","volume":"223","author":"Raman","year":"2021","journal-title":"J Infect Diseases."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1192","article-title":"Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study","volume":"9","author":"Shao","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1856058","article-title":"Effects of adjunct treatment with intravenous immunoglobulins on the course of severe COVID-19: results from a retrospective cohort study","volume":"37","author":"Esen","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627844","article-title":"High-dose intravenous immunoglobulin in severe coronavirus disease 2019: A multicenter retrospective study in China","volume":"12","author":"Cao","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1764472","article-title":"Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report","volume":"31","author":"Daneshpazhooh","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.05.006","article-title":"Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series","volume":"548","author":"Mohtadi","year":"2020","journal-title":"Virology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"107205","DOI":"10.1016\/j.intimp.2020.107205","article-title":"Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial","volume":"90","author":"Tabarsi","year":"2021","journal-title":"Int Immunopharmacology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00440-9","article-title":"Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Mazeraud","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1602434","article-title":"Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages","volume":"16","author":"Saha","year":"2020","journal-title":"Hum Vaccin Immunother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41419-020-2249-y","article-title":"Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy","volume":"11","author":"Das","year":"2020","journal-title":"Cell Death Disease."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.04.002","article-title":"Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation","volume":"132","author":"MacMillan","year":"2009","journal-title":"Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00004","article-title":"Intravenous immunoglobulin and immunomodulation of b-cell - in vitro and in vivo effects","volume":"6","author":"Mitrevski","year":"2015","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/HAB-160293","article-title":"The effect of intravenous immunoglobulin (IVIG) on ex vivo activation of human leukocytes","volume":"24","author":"Basyreva","year":"2016","journal-title":"Hum Antibodies"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb05173.x","article-title":"Stimulation of the respiratory burst and promotion of bacterial killing in human granulocytes by intravenous immunoglobulin preparations","volume":"79","author":"Mar\u00f3di","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-019604","article-title":"Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNF\u03b1-dependent and fc-receptor\u2013independent way","volume":"109","author":"Jarius","year":"2007","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-200003000-00012","article-title":"Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcgammaRII and FcgammaRIII receptors","volume":"47","author":"Nemes","year":"2000","journal-title":"Pediatr Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4A0813-422RRR","article-title":"Enhancement of neutrophil autophagy by an IVIG preparation against multidrug-resistant bacteria as well as drug-sensitive strains","volume":"98","author":"Itoh","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00697.x","article-title":"Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro","volume":"114","author":"Teeling","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026469","article-title":"A differential concentration-dependent effect of IVIg on neutrophil functions: Relevance for anti-microbial and anti-inflammatory mechanisms","volume":"6","author":"Casulli","year":"2011","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.700429","article-title":"Immunomodulation: Immunoglobulin preparations suppress hyperinflammation in a COVID-19 model via Fc\u03b3RIIA and Fc\u03b1RI","volume":"12","author":"Bohl\u00e4nder","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1602292","article-title":"Pharmaceutical immunoglobulins reduce neutrophil extracellular trap formation and ameliorate the development of MPO-ANCA-associated vasculitis","volume":"30","author":"Uozumi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1767CI","article-title":"Fifty years of research in ARDS. is acute respiratory distress syndrome a preventable disease","volume":"195","author":"Yadav","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/978-3-030-37323-8_5","article-title":"ARDS subphenotypes: Understanding a heterogeneous syndrome","volume":"24","author":"Wilson","year":"2020","journal-title":"Crit Care"},{"key":"B52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jointm.2021.01.002","article-title":"Corticosteroids for COVID-19","volume":"1","author":"Annane","year":"2021","journal-title":"J Intensive Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00060","article-title":"Dexamethasone inhibits s. aureus-induced neutrophil extracellular pathogen-killing mechanism, possibly through toll-like receptor regulation","volume":"8","author":"Wan","year":"2017","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01576-3","article-title":"Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19","volume":"28","author":"Sinha","year":"2022","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S284941","article-title":"Studying neutrophil function in vitro: Cell models and environmental factors","volume":"14","author":"Blanter","year":"2021","journal-title":"J Inflamm Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297920100065","article-title":"NETosis: Molecular mechanisms, role in physiology and pathology","volume":"85","author":"Vorobjeva","year":"2020","journal-title":"Biochem (Mosc)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.936734","article-title":"Case series of successful intravenous immunoglobulin (IVIG) treatment in 4 pregnant patients with severe COVID-19-Induced hypoxia","volume":"23","author":"Geriak","year":"2022","journal-title":"Am J Case Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.12788\/jcom.0094","article-title":"Intravenous immunoglobulin in treating nonventilated COVID-19 patients with moderate-to-Severe hypoxia: A pharmacoeconomic analysis","volume":"29","author":"Poremba M","year":"2022","journal-title":"J Clin Outcomes Management."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00450-1","article-title":"Intravenous immunoglobulin therapy for COVID-19 ARDS","volume":"10","author":"Wilfong","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00549-X","article-title":"Why the application of IVIG might be beneficial in patients with COVID-19","volume":"10","author":"Kindgen-Milles","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200652","article-title":"Targeting potential drivers of COVID-19: Neutrophil extracellular traps","volume":"217","author":"Barnes","year":"2020","journal-title":"J Exp Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10020-020-00215-w","article-title":"Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series","volume":"26","author":"Weber","year":"2020","journal-title":"Mol Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120389","article-title":"Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm","volume":"267","author":"Lee","year":"2021","journal-title":"Biomaterials"},{"key":"B64","doi-asserted-by":"publisher","first-page":"109016","DOI":"10.1016\/j.clim.2022.109016","article-title":"Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure","volume":"238","author":"Gavriilidis","year":"2022","journal-title":"Clin Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-017-2780-z","article-title":"The neutrophil: one cell on many missions or many cells with different agendas","volume":"371","author":"Christoffersson","year":"2018","journal-title":"Cell Tissue Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176472","article-title":"In vitro induction of NETosis: Comprehensive live imaging comparison and systematic review","volume":"12","author":"Hoppenbrouwers","year":"2017","journal-title":"PloS One"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2019.84017","article-title":"Potent NETosis inducers do not show synergistic effects in vitro","volume":"44","author":"Pruchniak","year":"2019","journal-title":"Cent Eur J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.993720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T08:18:28Z","timestamp":1666253908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.993720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2022.993720"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.993720","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"993720"}}